AN2 Therapeutics (ANTX)
(Delayed Data from NSDQ)
$2.55 USD
-0.01 (-0.39%)
Updated Jul 31, 2024 04:00 PM ET
4-Sell of 5 4
D Value C Growth A Momentum C VGM
Income Statements
Fiscal Year end for AN2 Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 70 | 42 | 22 | 7 | 0 |
Income After Depreciation & Amortization | -70 | -42 | -22 | -7 | 0 |
Non-Operating Income | 5 | 1 | 0 | -6 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -65 | -41 | -22 | -14 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -65 | -41 | -22 | -14 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -65 | -41 | -22 | -14 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -72 | -43 | -22 | -7 | 0 |
Depreciation & Amortization (Cash Flow) | -3 | -1 | 0 | 0 | NA |
Income After Depreciation & Amortization | -70 | -42 | -22 | -7 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 23.60 | 15.34 | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -2.74 | -2.79 | NA | NA | NA |
Diluted Net EPS (GAAP) | -2.74 | -2.79 | -10.64 | NA | NA |
Fiscal Year end for AN2 Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 18.30 | 18.82 | 18.18 | 16.60 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -18.30 | -18.82 | -18.18 | -16.60 |
Non-Operating Income | NA | 1.68 | 1.92 | 1.47 | 0.80 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -16.62 | -16.90 | -16.71 | -15.80 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -16.62 | -16.90 | -16.71 | -15.80 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -16.62 | -16.90 | -16.71 | -15.80 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 29.76 | 29.74 | 25.65 | 19.50 |
Diluted EPS Before Non-Recurring Items | NA | -0.56 | -0.57 | -0.65 | -0.81 |
Diluted Net EPS (GAAP) | NA | -0.56 | -0.49 | -0.65 | -0.81 |